drugset / Trial / NCT03192202
AFM13 in Relapsed/Refractory Cutaneous Lymphomas
Non-randomizedSequentialOpen-labelTreatment
Summary
The investigators plan to investigate AFM13 and evaluate its ability to facilitate and redirect the Natural Killer (NK) cells in eliminating CD30-positive lymphoma targets in the skin and, by inference, other organs involved by the lymphoma.
Timeline
- Start
- 2017-07-17
- Primary completion
- 2020-04-01
- Completion
- 2020-04-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ACIMTAMIG | Protein / enzyme biologic | 1.5 mg/kg | Intravenous |
| Subject | ACIMTAMIG | Protein / enzyme biologic | 7 mg/kg | Intravenous |
| Subject | ACIMTAMIG | Protein / enzyme biologic | 200 mg | Intravenous |